These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 26038137)
1. [Imatinib mesylate for chronic myeloid leukemia: in patients with initial treatment versus those with Recombinant Human IFN-α2b treatment failure]. Jiang JH; Xu WL; Qian WB Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 44(2):179-83. PubMed ID: 26038137 [TBL] [Abstract][Full Text] [Related]
3. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965 [TBL] [Abstract][Full Text] [Related]
4. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453 [TBL] [Abstract][Full Text] [Related]
5. [A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-α]. Wu SH; Zheng CP; Xu J Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):311-5. PubMed ID: 22781725 [TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418 [TBL] [Abstract][Full Text] [Related]
7. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Kantarjian HM; Cortes JE; O'Brien S; Luthra R; Giles F; Verstovsek S; Faderl S; Thomas D; Garcia-Manero G; Rios MB; Shan J; Jones D; Talpaz M Blood; 2004 Oct; 104(7):1979-88. PubMed ID: 15198956 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia]. Ye YF; Lyu XM; Li HL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):456-461. PubMed ID: 33812415 [TBL] [Abstract][Full Text] [Related]
9. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Roy L; Guilhot J; Krahnke T; Guerci-Bresler A; Druker BJ; Larson RA; O'Brien S; So C; Massimini G; Guilhot F Blood; 2006 Sep; 108(5):1478-84. PubMed ID: 16627756 [TBL] [Abstract][Full Text] [Related]
10. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Kantarjian HM; Talpaz M; O'Brien S; Jones D; Giles F; Garcia-Manero G; Faderl S; Ravandi F; Rios MB; Shan J; Cortes J Blood; 2006 Sep; 108(6):1835-40. PubMed ID: 16709931 [TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Cohen MH; Johnson JR; Pazdur R Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523 [TBL] [Abstract][Full Text] [Related]
12. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate]. Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149 [TBL] [Abstract][Full Text] [Related]
13. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666 [TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283 [TBL] [Abstract][Full Text] [Related]
15. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate]. Chen ZC; You Y; Zhu XM; Li QB; Li WM; Zou P Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):1003-6. PubMed ID: 18478917 [TBL] [Abstract][Full Text] [Related]
16. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia]. Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902 [TBL] [Abstract][Full Text] [Related]